• Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers. Eliquis is a Factor Xa inhibitor. Anticoagulation markers and plasma concentration levels of Eliquis indicate that PRT 4445 results in a rapid, sustained, dose-related reversal of anticoagulant activity of Eliquis. There were no serious adverse events.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter